ACADIA Pharmaceuticals Inc
F:DR6
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
ACADIA Pharmaceuticals Inc
F:DR6
|
US |
|
Banco Santander Brasil SA
BOVESPA:SANB4
|
BR |
|
R
|
Riber SA
XBER:RI7
|
FR |
|
I
|
Ionis Pharmaceuticals Inc
SWB:ISI
|
US |
|
G
|
Graham Holdings Co
DUS:WPOB
|
US |
|
UCapital24 SpA
MIL:U24
|
IT |
|
Steel Dynamics Inc
NASDAQ:STLD
|
US |
|
A
|
argenx SE
F:1AE
|
NL |
|
P
|
PDF Solutions Inc
SWB:PD9
|
US |
|
E
|
Exelon Corp
LSE:0IJN
|
US |
|
S
|
SFL Corporation Ltd
XHAM:UG6
|
BM |
|
Namura Shipbuilding Co Ltd
F:8AF
|
JP |
|
C
|
Chemours Co
BMV:CC
|
US |
|
V
|
Veeva Systems Inc
SWB:VEE
|
US |
|
ZTO Express (Cayman) Inc
HKEX:2057
|
CN |
|
A
|
Automatic Data Processing Inc
XBER:ADP
|
US |
|
Heineken NV
LSE:0O26
|
NL |
|
C
|
Centene Corp
LSE:0HVB
|
US |
ACADIA Pharmaceuticals Inc
ACADIA Pharmaceuticals is a biopharmaceutical company that develops and sells prescription medicines for brain and nervous system disorders. Its main products are used by specialists and caregivers treating conditions that are hard to address with older drugs, especially diseases with limited treatment options. The company makes money by selling its approved medicines through the prescription drug supply chain, mainly to wholesalers, pharmacies, and health plans that reimburse patient prescriptions. Its best-known products include treatments for Parkinson’s disease psychosis and Rett syndrome, so its business depends on doctors choosing its drugs, insurers covering them, and the company keeping them approved and available. What makes ACADIA different is that it is not a broad drug maker with many categories of products. It is a focused neuroscience company that builds value around a small number of specialized medicines for rare or difficult brain disorders, where success depends on regulatory approval, physician adoption, and ongoing use in a narrow patient population.
ACADIA Pharmaceuticals is a biopharmaceutical company that develops and sells prescription medicines for brain and nervous system disorders. Its main products are used by specialists and caregivers treating conditions that are hard to address with older drugs, especially diseases with limited treatment options.
The company makes money by selling its approved medicines through the prescription drug supply chain, mainly to wholesalers, pharmacies, and health plans that reimburse patient prescriptions. Its best-known products include treatments for Parkinson’s disease psychosis and Rett syndrome, so its business depends on doctors choosing its drugs, insurers covering them, and the company keeping them approved and available.
What makes ACADIA different is that it is not a broad drug maker with many categories of products. It is a focused neuroscience company that builds value around a small number of specialized medicines for rare or difficult brain disorders, where success depends on regulatory approval, physician adoption, and ongoing use in a narrow patient population.
Revenue: ACADIA reported first-quarter total revenue of $268 million, up 11% year over year on an adjusted basis, and reaffirmed full-year 2026 revenue guidance of $1.22 billion to $1.28 billion.
DAYBUE momentum: DAYBUE generated $101 million in sales, up 20% year over year, helped by record unique patients, strong referrals, and an early launch of DAYBUE STIX that management said is exceeding their initial expectations.
NUPLAZID recovery: NUPLAZID sales were $167 million, up 6% year over year on an adjusted basis, with management saying refill timing was temporarily slow early in the quarter but has now normalized.
Pipeline catalyst: The company reiterated that Phase II data for remlifanserin in Alzheimer's disease psychosis should come in the August to October 2026 window, and said the trial is nearing the final stages of enrollment.
Capital and BD: ACADIA ended the quarter with $851 million in cash and said that balance gives it flexibility for business development, including acquisitions, licenses, and partnerships.
